How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/juvenile-idiopathic-arthritis-extended-oligoarthritis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Juvenile idiopathic arthritis, extended oligoarthritis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Juvenile idiopathic arthritis, extended oligoarthritis (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Juvenile idiopathic arthritis, extended oligoarthritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xeljanz	tofacitinib	Pfizer	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Xeljanz	Tofacitinib Citrate	Pfizer	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Roactemra	tocilizumab	Roche	Interleukin-6 Receptor Antagonist [EPC]	Interleukin-6 receptor	2010-01-01
Tasocitinib	Tasocitinib	Pfizer		Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Juvenile idiopathic arthritis, extended oligoarthritis
· 1 drug in Juvenile idiopathic arthritis, extended oligoarthritis
Roche · 1 drug in Juvenile idiopathic arthritis, extended oligoarthritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Juvenile idiopathic arthritis, extended oligoarthritis:

Cite this brief

Drug Landscape (2026). Juvenile idiopathic arthritis, extended oligoarthritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/juvenile-idiopathic-arthritis-extended-oligoarthritis. Accessed 2026-06-10.

Juvenile idiopathic arthritis, extended oligoarthritis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing